EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Condition(s):Lung CancerLast Updated:May 1, 2015Completed
Hide Studies Not Open or Pending
Condition(s):Lung CancerLast Updated:May 1, 2015Completed
Condition(s):Esophageal CancerLast Updated:November 29, 2022Recruiting
Condition(s):Prostate CancerLast Updated:February 28, 2024Not yet recruiting
Condition(s):To Correlate RPM Respiratory-gating Methods Analyses, Treatment Response, and Normal Tissue Metabolic Effect.; Application in Clinical Outcomes and Prediction of Prognosis.Last Updated:February 14, 2014Unknown status
Condition(s):Plasma Cell DisorderLast Updated:March 15, 2024Not yet recruiting
Condition(s):Advanced Solid Tumor; Head and Neck Squamous Cell CarcinomaLast Updated:March 6, 2024Active, not recruiting
Condition(s):Glioma; Glioblastoma; Glioblastoma Multiforme; GBM; Brain CancerLast Updated:November 21, 2023Active, not recruiting
Condition(s):Malignant MelanomaLast Updated:July 25, 2017Completed
Condition(s):Hepatocellular CarcinomaLast Updated:February 21, 2019Unknown status
Condition(s):Carcinoma, HepatocellularLast Updated:May 3, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.